Alcohol-Associated Liver Disease

Alcohol-Associated Liver Disease: Comprehensive Summary

Presenter: Ashwani Singal, MD

Format: CME/Medical Education Lecture (~60 minutes)

1. Main Clinical Topics Discussed

• Epidemiology and healthcare burden of alcohol-associated liver disease (ALD)
• Spectrum of ALD from steatosis to cirrhosis and hepatocellular carcinoma
• Risk factors, protective factors, and genetic modifiers
• Screening tools for alcohol use disorder (AUD) and liver disease
• Diagnosis of ALD and alcoholic hepatitis
• Medical management and emerging therapies
• Dual-disorder framework: AUD + liver disease
• Prognosis, liver transplantation, and public health policy

2. Key Learning Points, Guidelines, and Recommendations

Epidemiology

• ~66–70% of U.S. adults have consumed alcohol at some point
• AUD prevalence: ~2% worldwide; ~4% in Europe
• ALD accounts for 27% of all cirrhosis deaths worldwide; ~40% in Europe, 30–40% in South America
• ALD is the leading indication for liver transplantation in the U.S.; in 2018, 40–45% of U.S. liver transplants were ALD-related
• Hospitalizations for both alcohol-associated cirrhosis and alcoholic hepatitis are increasing, particularly among:

- Adults <35 years of age

- Females and Hispanic populations

- Presenting with more severe disease, including acute-on-chronic liver failure (ACLF)

Risk Factors

• Alcohol dose-response: Risk of cirrhosis increases modestly up to ~100 g/day, then rises exponentially above that threshold
• Only 10–20% of heavy drinkers develop cirrhosis, indicating important modifying factors
• Sex: Females are more susceptible

- After >15 years of heavy drinking (>10 drinks/day), cirrhosis risk: 3% in men vs. 5% in women

- Attributed to lower gastric alcohol dehydrogenase, higher body fat percentage, and higher blood alcohol concentrations per given dose

• Genetics:

- PNPLA3 is the most important gene influencing both risk and severity of ALD (shared with NAFLD)

- Other implicated genes: TM6SF2, MBOAT7

• Drinking patterns: Daily > intermittent; drinking after age 40; hard liquor/beer > wine; binge drinking history; drinking on an empty stomach
• Comorbidities:

- Concomitant hepatitis C has a synergistic effect on cirrhosis risk

- BMI + alcohol = ~10× synergistic increase in cirrhosis risk (vs. ~3.7× for alcohol alone)

Protective Factors

• Coffee consumption: Multiple meta-analyses and multicenter studies confirm a dose-dependent hepatoprotective effect in drinkers
• Marijuana: Emerging and controversial data suggest a possible protective effect regarding hepatic susceptibility

3. Clinical Data and Statistics Cited

4. Screening and Diagnostic Recommendations

Alcohol Use Disorder Screening

• AUDIT-C (first 3 questions of full AUDIT tool):

- Score >4 in females or >5 in males: high likelihood of AUD

- Full AUDIT: <8 = no AUD;